The good, the bad, and the opportunities of the complement system in neurodegenerative disease

• Published in: Journal of neuroinflammation 2020-11, Vol.17 (1), p.354, Article 354
• Main Authors: Schartz, Nicole D, Tenner, Andrea J
• Format: Article
• Language: English
• Subjects: Aging; Animal models; Animals; Binding sites; Blood-brain barrier; Central nervous system; Complement activation; Complement Activation - drug effects; Complement Activation - physiology; Complement component C1q; Complement system; Complement System Proteins - biosynthesis; Complement System Proteins - immunology; Degeneration; Disease; Enzymes; Humans; Immune clearance; Immune response; Inflammation; Innate immunity; Lectins; Nervous system; Neurodegenerative diseases; Neurodegenerative Diseases - drug therapy; Neurodegenerative Diseases - immunology; Neurodegenerative Diseases - metabolism; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Pathogens; Peptides; Proteins; Review; Synapse elimination; Synapses
• ISSN: 1742-2094; 1742-2094
• DOI: 10.1186/s12974-020-02024-8

The complement cascade is a critical effector mechanism of the innate immune system that contributes to the rapid clearance of pathogens and dead or dying cells, as well as contributing to the extent and limit of the inflammatory immune response. In addition, some of the early components of this cascade have been clearly shown to play a beneficial role in synapse elimination during the development of the nervous system, although excessive complement-mediated synaptic pruning in the adult or injured brain may be detrimental in multiple neurogenerative disorders. While many of these later studies have been in mouse models, observations consistent with this notion have been reported in human postmortem examination of brain tissue. Increasing awareness of distinct roles of C1q, the initial recognition component of the classical complement pathway, that are independent of the rest of the complement cascade, as well as the relationship with other signaling pathways of inflammation (in the periphery as well as the central nervous system), highlights the need for a thorough understanding of these molecular entities and pathways to facilitate successful therapeutic design, including target identification, disease stage for treatment, and delivery in specific neurologic disorders. Here, we review the evidence for both beneficial and detrimental effects of complement components and activation products in multiple neurodegenerative disorders. Evidence for requisite co-factors for the diverse consequences are reviewed, as well as the recent studies that support the possibility of successful pharmacological approaches to suppress excessive and detrimental complement-mediated chronic inflammation, while preserving beneficial effects of complement components, to slow the progression of neurodegenerative disease.